Lycke J - Search Results

1

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A. Axelsson M, et al. Among authors: lycke j. Mult Scler. 2014 Jan;20(1):43-50. doi: 10.1177/1352458513490544. Epub 2013 May 23. Mult Scler. 2014. PMID: 23702432

2

No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis.

Svenningsson A, Lycke J, Svennerholm B, Gronowitz S, Andersen O. Svenningsson A, et al. Among authors: lycke j. Ann Neurol. 1992 Nov;32(5):711-4. doi: 10.1002/ana.410320518. Ann Neurol. 1992. PMID: 1333176

3

Use of immunoreactive synthetic HTLV-1 peptides in the search for antibody reactivity in multiple sclerosis.

Lycke J, Andersen O, Svennerholm B, Ben-Menachem E, Horal P, Vahlne A. Lycke J, et al. Acta Neurol Scand. 1992 Jan;85(1):44-54. doi: 10.1111/j.1600-0404.1992.tb03994.x. Acta Neurol Scand. 1992. PMID: 1546533

4

Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden.

Svenningsson A, Runmarker B, Lycke J, Andersen O. Svenningsson A, et al. Among authors: lycke j. Acta Neurol Scand. 1990 Sep;82(3):161-8. doi: 10.1111/j.1600-0404.1990.tb04483.x. Acta Neurol Scand. 1990. PMID: 2270743

5

Human spumaretrovirus antibody reactivity in multiple sclerosis.

Lycke J, Svennerholm B, Svenningsson A, Muranyi W, Flügel RM, Andersen O. Lycke J, et al. J Neurol. 1994 Feb;241(4):204-9. doi: 10.1007/BF00863769. J Neurol. 1994. PMID: 8195818

6

Possible association of HTLV-I infection and dementia.

Lycke J, Svennerholm B, Svenningsson A, Horal P, Nordqvist-Brandt E, Andersen O. Lycke J, et al. Acta Neurol Scand. 1993 Sep;88(3):199-203. doi: 10.1111/j.1600-0404.1993.tb04216.x. Acta Neurol Scand. 1993. PMID: 8256556

7

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, Gjörstrup P, Ekholm S. Andersen O, et al. Among authors: lycke j. Neurology. 1996 Oct;47(4):895-900. doi: 10.1212/wnl.47.4.895. Neurology. 1996. PMID: 8857715 Clinical Trial.

8

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Aström M, Gjörstrup P, Ekholm S. Andersen O, et al. Among authors: lycke j. Mult Scler. 1996 Jul;1(6):348. doi: 10.1177/135245859600100613. Mult Scler. 1996. PMID: 9345415 Clinical Trial. No abstract available.

9

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Lycke JN, et al. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402-4. doi: 10.1136/jnnp.64.3.402. J Neurol Neurosurg Psychiatry. 1998. PMID: 9527161 Free PMC article.

10

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, Christensen T, Ekholm S, Haahr S, Höllsberg P, Bergström T, Svennerholm B, Jakobsen J. Bech E, et al. Among authors: lycke j. Neurology. 2002 Jan 8;58(1):31-6. doi: 10.1212/wnl.58.1.31. Neurology. 2002. PMID: 11781402 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters